Generally speaking, while NMIBCs have a more favourable prognosis compared to their MI counterpart, they are not the same and seem to behave differently (i.e. some are relatively indolent, others have aggressive features). In this episode, Prof. Paolo Gontero explains why. He will also discuss the following:

• What is the current, best-recommended way for risk stratification of NMIBCs
• If there is a way to predict the risk of recurrence of a NMIBC
• How to tailor treatment recommendations

Guest: Prof. Paolo Gontero, member of the EAU Guidelines panel for Non-Muscle Invasive Bladder Cancer